Aptamers Market to Surge Past US$ 10,407 Million by 2025 due to Widened Application Area

Aptamers is revolutionizing the healthcare industry by providing the affinity towards a desired target with high selectivity and specificity. This enable research scientists to gain interest towards the field of aptamers technology with increasing support from public-private organizations. Companies such as Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, and SomaLogic, Inc. are collaborating with each other or independent research organizations and institutes to speed-up the research activities for the treatment of a number of diseases in order to decrease the time to market (TTM).

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/774

Aptamers offer significant advantages related to protein therapeutics in terms of synthetic accessibility, size, and modification by medicinal chemistry which in turn aid in developing highly effective therapy. Continuous investment and development of novel aptamers by market players is propelling the market growth over the forecast period. Ophthotech is developing novel therapeutics Fovista and Zimura (an aptamer), used to treat eye diseases. Furthermore, advancements in Systemic Evolution of Ligands by Exponential Enrichment (SELEX) process to extract high-quality aptamers for a more diverse range of applications and government support in developed regions are anticipated to fuel utilization of these products, leading to market growth.

Increasing number of applications will drive the overall aptamers market

Aptamer products can be used as biosensors, diagnostics, research agents or can be considered as a tool for biomarker or drug discovery. It can also be used for targeted therapeutics and bio-industrial applications. Use of in-vivo aptamer have a vast advantages by avoiding the majority of the bench testing, saving several years and approximately 35% of the R&D cost. It permits the natural selection of drug candidates in whole animal models, which reduces the false starts and required fewer animals needed for drug evaluation. All these factors have attracted a large number of companies to invest in this market. Moreover, growing incidence of life-threatening diseases such cancer has directed many companies to introduce new detection assays based on aptamer therapy which will help to booster the growth of the aptamer market. In March 2017, Aptamer Sciences, Inc. unveiled multiprotein biomarker assay by using this technology for the detection of lung cancer. However, stringent regulations related the use of aptamer and low awareness about these molecules in emerging economies such as Asia-Pacific and Middle East and Africa are some of the factors that may pose a challenge to the growth of the market.

Continuous innovations and collaborations among manufacturers and research institutes is a prominent factor to fuel the aptamers market

Continuous investments by biotechnological and pharmaceutical companies and introduction of next generation products are the major factors that boost the growth of the aptamer market. Growing number of academic research laboratories investigating the potential of aptamers and rising number of products under clinical investigation also increased the rate of market penetration and demand for aptamers across the globe. For Instance, Ophthotech Corporation’s Fovista, a chemically synthesized nucleic acid aptamer, is currently under clinical investigation.

North America hold the maximum share of aptamers market in 2016, owing to presence of major key players and strategic collaborations among them, followed by Europe. Asia Pacific is also expected to grow at a substantial rate due to increased investments in R&D and setting up of in-house manufacturing and R&D facilities.

Ask for customization @ https://www.coherentmarketinsights.com/insight/request-sample/774

Key vendors in the aptamers market are collaborating with each other or independent research organizations and institutes to retain or increase their market share. For example, in March 2014, Siva Therapeutics initiated a research collaboration with SomaLogic, Inc. to determine the ability of SomaLogic’s SOMAmer (Slow-off Rate Modified Aptamer) reagents to actively target gold nanorods to solid tumors. This is expected to create more opportunity for aptamer for a more diverse range of applications in the near future.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.